Experimental combo for tough lung cancer hits dead end

NCT ID NCT05636267

Terminated Disease control Sponsor: Akeso Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested two immunotherapy drugs, AK119 and AK112, with or without chemotherapy, in 59 people with a specific type of advanced lung cancer (EGFR-mutant non-squamous NSCLC) that had stopped responding to standard targeted pills. The goal was to see if the combination was safe and could shrink tumors. However, the trial was terminated early, so we don't have full results on how well it worked.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AK119 and AK112 (immunotherapy drugs) with or without chemotherapy (pemetrexed and carboplatin)
What this could lead to: If successful, this could offer a new treatment option for people with a specific type of lung cancer that stopped responding to standard targeted therapy.
What could go wrong: This trial was terminated early, so results are limited. It was also a small, early-phase study, so even if data were available, much more research would be needed to confirm any benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EGFR-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung adenocarcinoma non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC

Contacts and locations

Locations

Guangdong Provincial People's Hospital

Guangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.